Myelofibrosis - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 161 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Myelofibrosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Myelofibrosis - Pipeline Review, H2 2014', provides an overview of the Myelofibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myelofibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Myelofibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myelofibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myelofibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Myelofibrosis Overview 9
Therapeutics Development 10
Pipeline Products for Myelofibrosis - Overview 10
Pipeline Products for Myelofibrosis - Comparative Analysis 11
Myelofibrosis - Therapeutics under Development by Companies 12
Myelofibrosis - Therapeutics under Investigation by Universities/Institutes 14
Myelofibrosis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Myelofibrosis - Products under Development by Companies 18
Myelofibrosis - Products under Investigation by Universities/Institutes 19
Myelofibrosis - Companies Involved in Therapeutics Development 20
Acceleron Pharma, Inc. 20
AstraZeneca PLC 21
Bristol-Myers Squibb Company 22
Celgene Corporation 23
CTI BioPharma Corp. 24
Geron Corporation 25
Gilead Sciences, Inc. 26
Incyte Corporation 27
Italfarmaco S.p.A. 28
KaloBios Pharmaceuticals, Inc. 29
MEI Pharma, Inc. 30
Nippon Shinyaku Co., Ltd. 31
Novartis AG 32
Onconova Therapeutics, Inc. 33
Pfizer Inc. 34
PharmaEssentia Corporation 35
Promedior, Inc. 36
Stemline Therapeutics, Inc. 37
Threshold Pharmaceuticals, Inc. 38
Myelofibrosis - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
AZD-1480 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BMS-911543 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
buparlisib hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
erismodegib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
evofosfamide - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
givinostat - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
glasdegib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
imetelstat sodium - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
INCB-39110 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
KB-004 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
LCL-161 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
luminespib - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
momelotinib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
NS-018 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pacritinib - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
panobinostat - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
peginterferon alfa-2b - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
pomalidomide - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
pracinostat - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
PRM-151 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
rigosertib sodium - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
SL-401 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
sotatercept - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Myelofibrosis - Recent Pipeline Updates 110
Myelofibrosis - Dormant Projects 148
Myelofibrosis - Discontinued Products 149
Myelofibrosis - Product Development Milestones 150
Featured News & Press Releases 150
Sep 02, 2014: Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Myelofibrosis 150
Aug 07, 2014: FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis 150
Jul 01, 2014: CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis 152
Jun 05, 2014: Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of European Hematology Association 153
May 30, 2014: Promedior to Present Positive Preliminary Phase 2 Data for PRM-151 in Myelofibrosis at ASCO Annual Meeting 153
May 15, 2014: Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at ASCO 154
Mar 20, 2014: Geron Reports Myelofibrosis IST Placed on Partial Clinical Hold 155
Mar 03, 2014: CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts 156
Jan 08, 2014: Promedior Attains Patient Enrollment Milestone in Phase 2 Clinical Study of PRM-151 in Myelofibrosis 157
Dec 09, 2013: Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte's Oral JAK1 Inhibitor in Patients with Myelofibrosis 158
Appendix 160
Methodology 160
Coverage 160
Secondary Research 160
Primary Research 160
Expert Panel Validation 160
Contact Us 161
Disclaimer 161

List of Tables
Number of Products under Development for Myelofibrosis, H2 2014 10
Number of Products under Development for Myelofibrosis - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Myelofibrosis - Pipeline by Acceleron Pharma, Inc., H2 2014 20
Myelofibrosis - Pipeline by AstraZeneca PLC, H2 2014 21
Myelofibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2014 22
Myelofibrosis - Pipeline by Celgene Corporation, H2 2014 23
Myelofibrosis - Pipeline by CTI BioPharma Corp., H2 2014 24
Myelofibrosis - Pipeline by Geron Corporation, H2 2014 25
Myelofibrosis - Pipeline by Gilead Sciences, Inc., H2 2014 26
Myelofibrosis - Pipeline by Incyte Corporation, H2 2014 27
Myelofibrosis - Pipeline by Italfarmaco S.p.A., H2 2014 28
Myelofibrosis - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2014 29
Myelofibrosis - Pipeline by MEI Pharma, Inc., H2 2014 30
Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 31
Myelofibrosis - Pipeline by Novartis AG, H2 2014 32
Myelofibrosis - Pipeline by Onconova Therapeutics, Inc., H2 2014 33
Myelofibrosis - Pipeline by Pfizer Inc., H2 2014 34
Myelofibrosis - Pipeline by PharmaEssentia Corporation, H2 2014 35
Myelofibrosis - Pipeline by Promedior, Inc., H2 2014 36
Myelofibrosis - Pipeline by Stemline Therapeutics, Inc., H2 2014 37
Myelofibrosis - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 38
Assessment by Monotherapy Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 43
Number of Products by Stage and Route of Administration, H2 2014 45
Number of Products by Stage and Molecule Type, H2 2014 47
Myelofibrosis Therapeutics - Recent Pipeline Updates, H2 2014 110
Myelofibrosis - Dormant Projects, H2 2014 148
Myelofibrosis - Discontinued Products, H2 2014 149